33% ORR achieved in second-line KRAS-mutant MSS colorectal cancer—triple historical response rates for Avastin + FOLFIRI of 6-11%
Translational analysis shows pelareorep enhances KRAS-mutant–specific T-cell activity, providing mechanistic support for clinical responses
Data strengthen pelareorep’s potential to transform a multi–billion dollar underserved colorectal cancer market
https://finance.yahoo.com/news/oncolytics-biotech-announces-promising-efficacy-140000111.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.